Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected to grow to nearly $10 Billion by 2028 Carlsbad, CA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has received a No Objection Letter from Health Canada for its Phase 1 human clinical study for PALI-2108 for the treatment of UC. “We are thrilled to receive a No Objection Letter from Health Canada in response to our Clinical Trial Application. This achievement marks the most important milestone to date for our PALI-2
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) [Yahoo! Finance]Yahoo! Finance
- Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)GlobeNewswire
- Palisade Bio, Inc. (NASDAQ: PALI) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $38.00 price target on the stock.MarketBeat
- Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit [Yahoo! Finance]Yahoo! Finance
- Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitGlobeNewswire
PALI
Analyst Actions
- 11/13/24 - Maxim Group
PALI
Sec Filings
- 11/21/24 - Form S-1/A
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- PALI's page on the SEC website